Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thousand Oaks Holding Company
Nantong, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
As a CDMO, Thousand Oaks Biologics/Biopharmaceuticals enables partners via advanced CMC capabilities, with successful completion of multiple BLA projects and pre-approval inspections since 2021
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyFusion proteinAntibody-drug conjugateBiologic
- Industry
- Contract Manufacturing Organization
02
Partnerships
GeneQuantum Healthcare (ADC drug development, CMC conjugation technology)
Beyond the preview
Go deeper on Thousand Oaks Holding Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thousand Oaks Holding Company.